Long-Term Real-World Post-approval Safety Data of Multiple Biosimilars from One Marketing-Authorization Holder After More than 18 Years Since Their First Biosimilar Launch
ConclusionsThis is one of the largest reviews of post-approval biosimilar pharmacovigilance data to date by one MAH. The real-world experience of all eight marketed Sandoz biosimilars for up to 18 years demonstrates that Sandoz biosimilars can be used as safely as their respective reference biologics. Therefore, patients and healthcare providers can be confident in the clinical benefit and safety of Sandoz biosimilars. It is reasonable to believe that similar conclusions about safety may be reached for other biosimilars developed and approved to the high standards as are already in place by major health authorities such as...
Source: Drug Safety - October 30, 2023 Category: Drugs & Pharmacology Source Type: research
TNF- α blockage by etanercept restores spatial learning and reduces cellular degeneration in the hippocampus during liver cirrhosis
In conclusion, TNF-α is strongly involved in the development of liver cirrhosis and the associated encephalopathy. TNF-α blockers may be a promising approach for management of hepatic cirrhosis and its cerebral complications.PMID:37865039 | DOI:10.1016/j.tice.2023.102249 (Source: Tissue and Cell)
Source: Tissue and Cell - October 21, 2023 Category: Cytology Authors: Rehab Nady Rasha R Ahmed Nadia Moustafa Manal Abdul-Hamid Source Type: research
TNF- α blockage by etanercept restores spatial learning and reduces cellular degeneration in the hippocampus during liver cirrhosis
In conclusion, TNF-α is strongly involved in the development of liver cirrhosis and the associated encephalopathy. TNF-α blockers may be a promising approach for management of hepatic cirrhosis and its cerebral complications.PMID:37865039 | DOI:10.1016/j.tice.2023.102249 (Source: Tissue and Cell)
Source: Tissue and Cell - October 21, 2023 Category: Cytology Authors: Rehab Nady Rasha R Ahmed Nadia Moustafa Manal Abdul-Hamid Source Type: research
Etanercept-associated episcleritis: a pediatric case report of a paradoxical adverse reaction and review of the literature
We report a case of a 15-year-old boy with enthesitis-related arthritis and familial Mediterranean fever who presented with episcleritis and blepharitis while receiving etanercept treatment and subsequently showed dechallenge and rechallenge reactions. Therefore, ph ysicians should also be aware that episcleritis should be considered a paradoxical adverse reaction to etanercept and can occur in pediatric patients. We also reviewed the English literature to provide an overview and evaluate intervention options. (Source: Clinical Rheumatology)
Source: Clinical Rheumatology - October 17, 2023 Category: Rheumatology Source Type: research
Efficacy of biologic agents for palmoplantar psoriasis: a systematic review and network meta-analysis
CONCLUSIONS: Secukinumab, ixekizumab and infliximab are effective for PP. Research is warranted to produce evidence about the efficacy of biologics in PP and PPP.PMID:37842734 | DOI:10.1080/1744666X.2023.2272049 (Source: Expert Review of Clinical Immunology)
Source: Expert Review of Clinical Immunology - October 16, 2023 Category: Allergy & Immunology Authors: Sotirios G Tsiogkas Maria G Grammatikopoulou Katerina-Maria Kontouli Ioanna Minopoulou Dimitrios D Goulis Efterpi Zafiriou Dimitrios P Bogdanos Aikaterini Patsatsi Source Type: research
Management of Pediatric Psoriasis: A U.S. Survey Based on Visits from the National Ambulatory Medical Care Survey (NAMCS)
ConclusionUse of off-label treatments was common for pediatric psoriasis. Most children with psoriasis were treated with topicals, of which tacrolimus, an unapproved treatment, was the most common. The frequent use of tacrolimus could indicate an avoidance of corticosteroids in children. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - October 13, 2023 Category: Dermatology Source Type: research
Availability of comparative real-world evidence research in Medicare patients: implications for Centers for Medicare and Medicaid Services drug price negotiations
Conclusion: Our results demonstrate there is a considerable amount of comparative RWE for apixaban, rivaroxaban, and etanercept but limited comparative RWE for the other drugs set to undergo CMS price negotiations in 2026; additionally, our findings set up a number of next steps (e.g., risk of bias assessments) for further exploration of the available evidence base. Overall, CMS and manufacturers should consider proactively generating high-quality comparative RWE studies in the Medicare population to ensure that future price negotiations are based on robust evidence.PMID:37815792 | DOI:10.57264/cer-2023-0125 (Source: Journ...
Source: Journal of Comparative Effectiveness Research - October 10, 2023 Category: General Medicine Authors: Ashley Jaksa Patrick J Arena Nicolle Gatto Source Type: research
